本研究的目的是评估通过静脉输注移植到狗体内的同种异体间充质干细胞（MSC）的不良反应并检查其安全性。我们对各种临床评估进行了回顾性分析，包括体格检查、血液检查和射线照相，并在 6 个月的随访期间监测了 40 只接受静脉输注脂肪组织来源的客户拥有的狗的肿瘤形成情况。 2012年至2018年间用于治疗各种基础疾病的间充质干细胞（AT-MSCs）。首次间充质干细胞治疗后的6个月随访期间，通过临床评估、血液检测或放射学检查，未发现间充质干细胞治疗的明显不良反应治疗。此外，在此期间没有观察到新的肿瘤。据我们所知，本研究是第一个评估与静脉同种异体 AT-MSC 输注相关的安全性（≥6 个月）的研究。这些结果表明，同种异体 AT-MSC 输注可能是一种有用且相对安全的犬类治疗方法。© 2024。作者。

The aim of this study was to evaluate the adverse effects of allogeneic mesenchymal stem cells (MSCs) transplanted via intravenous infusion in dogs and examine their safety. We performed a retrospective analysis of various clinical assessments, including physical examination, blood tests, and radiographs, and monitored the formation of neoplasms during a 6-month follow-up period in 40 client-owned dogs that received intravenous infusion of adipose tissue-derived MSCs (AT-MSCs) for the treatment of various underlying diseases between 2012 and 2018.No significant adverse effects of MSC therapy were detected by clinical assessment, blood tests, or radiographic examination in the 6-month follow-up period after the first MSC treatment. Additionally no new neoplasms were observed during this period.To our knowledge, this study is the first to evaluate the safety aspects (≥ 6 months) associated with intravenous allogeneic AT-MSC infusion. These results suggest that allogenic AT-MSC infusion could be a useful and relatively safe therapeutic approach in canines.© 2024. The Author(s).